Form 4: Alzamend Neuro Director Sells Shares

Alzamend Neuro Director Lynne Fahey McGrath sold 30 shares of common stock at $2.29 per share on October 23, 2025.

Summary

• Lynne Fahey McGrath, a Director of Alzamend Neuro, Inc. (ALZN), reported a sale of common stock.
• The transaction involved the disposition of 30 shares of common stock.
• The shares were sold at a price of $2.29 per share.
• The transaction occurred on October 23, 2025.
• Following this transaction, Ms. McGrath beneficially owns 25 shares of common stock directly.
• The transaction was made pursuant to a contract, instruction, or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Sentiment

Score: 5

Explanation: The filing reports a routine insider transaction (sale of 30 shares) by a director under a Rule 10b5-1 plan. The volume is very small, and the pre-arranged nature of the sale mitigates any strong positive or negative sentiment regarding the company's prospects. Therefore, the sentiment is neutral.

Future Outlook

NA

Industry Context

This filing is a routine disclosure of an insider stock transaction and does not provide broader industry context or trends.

Stakeholder Impact

• Shareholders: Minimal impact due to the small volume of shares sold by a director, especially given it was executed under a Rule 10b5-1 plan.

Key Dates

Recommendation

The filing details a small, pre-scheduled sale of 30 shares by a director under a Rule 10b5-1 plan. This type of transaction is generally considered a personal financial decision and does not typically reflect a change in the company's fundamental outlook or performance. The volume is too insignificant to warrant a strong buy or sell recommendation. Therefore, a 'hold' recommendation is appropriate, suggesting no immediate action based solely on this filing.

Keywords

Alzamend Neuro, ALZN, Lynne Fahey McGrath, Director, Stock Sale, Insider Transaction, Form 4, Common Stock, Rule 10b5-1